KOC
GSK icon

Koss-Olinger Consulting’s GSK GSK Stock Holding History

Koss-Olinger Consulting’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
4,370
-44,174
-91% -$2.34M 0.02% 152
2026
Q1 		$2.68M Sell
48,544
-437
-0.9% -$23.7K 0.22% 44
2025
Q4 		$2.4M Sell
48,981
-16,686
-25% -$778K 0.19% 45
2025
Q3 		$2.52M Sell
65,667
-69
-0.1% -$2.69K 0.21% 54
2025
Q2 		$2.52M Sell
65,736
-2,460
-4% -$94K 0.21% 55
2025
Q1 		$2.64M Buy
68,196
+227
+0.3% +$8.31K 0.22% 50
2024
Q4 		$2.3M Buy
67,969
+5,583
+9% +$201K 0.2% 58
2024
Q3 		$2.55M Sell
62,386
-495
-0.8% -$20.3K 0.22% 56
2024
Q2 		$2.42M Buy
+62,881
New +$2.65M 0.22% 55
2024
Q1 		– Sell
-56,451
Closed -$2.09M – 142
2023
Q4 		$2.09M Buy
56,451
+3,734
+7% +$134K 0.21% 52
2023
Q3 		$1.91M Buy
52,717
+2,487
+5% +$88.3K 0.28% 45
2023
Q2 		$1.79M Sell
50,230
-820
-2% -$29.4K 0.21% 59
2023
Q1 		$1.82M Buy
51,050
+1,067
+2% +$37.3K 0.23% 49
2022
Q4 		$1.76M Buy
49,983
+32,935
+193% +$1.1M 0.25% 39
2022
Q3 		$502K Buy
17,048
+12,745
+296% +$483K 0.09% 100
2022
Q2 		$234K Sell
4,303
-1,536
-26% -$84.8K 0.04% 150
2022
Q1 		$318K Buy
5,839
+193
+3% +$10.5K 0.05% 145
2021
Q4 		$311K Buy
5,646
+14
+0.2% +$728 0.05% 152
2021
Q3 		$269K Buy
+5,632
New +$283K 0.04% 187

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Koss-Olinger Consulting's GSK Position: Q2 2026 in Review

Koss-Olinger Consulting reduced its GSK (GSK) stake by 91% in Q2 2026, selling an estimated $2.34M and leaving 4,370 shares worth $229K. The position accounts for 0.02% of the portfolio, ranked #152.

Koss-Olinger Consulting first reported a position in GSK in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.68M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Koss-Olinger Consulting held 4,370 shares of GSK worth $229K as of Q2 2026.
  • Koss-Olinger Consulting sold 44,174 GSK shares in Q2 2026, an estimated $2.34M.
  • GSK made up 0.02% of Koss-Olinger Consulting's portfolio in Q2 2026, its #152 holding.
  • Koss-Olinger Consulting first reported a position in GSK in Q3 2021 and has held it in 19 quarters since.
  • Koss-Olinger Consulting's GSK position peaked at $2.68M in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.